German Partner now aims to churn out around two billion doses this year.

That is up from an earlier target, off 1.3 billion.

The new goal comes as extra production lines come on stream by on Tech has also found ways to extract more doses from each vial off the product.

In a presentation Monday, the firm said it would use so called low dead space syringes.

They allow it to extract six doses from each standard vile instead of the usual five.

A new production site in Marburg, Germany, has also Bean acquired from Novartis.

It will become operational by the end of February and have an annual capacity off 750 million doses.

Contractors who supply ingredients have also ramped up capacity by on Tech said it had shipped 32.9 million doses as off Sunday.

A spokeswoman said the firm had actually made 50 million by the end of last year, but shipments were held back to avoid excess storage time.